🚀 Biointron is thrilled to collaborate with Carterra to bring you an exclusive live webinar: “Innovative Methods Advancing Discovery and Characterization of Antibodies”
- 🗓 Date: April 24, 2025
- ⏰ Time: 11am EDT // 8am PDT
Featuring:
- Long Xu, Ph.D. – R&D Director, Biointron
- Daniel Bedinger, Ph.D. – Sr. Manager Field Application Science, Carterra
This webinar will dive deep into technologies shaping the future of antibody drug discovery, including:
- Biointron’s latest platforms – VHH discovery, FCMES affinity maturation, AbDrop single B-cell sorting & more
- Carterra’s high-throughput solutions – enhancing efficiency, quality, and scalability
📌 Save your spot now: https://zoom.us/webinar/register/WN_hNjZT_-aQmiKEuo5l4DxTA#/registration
Abstract:
The rapid development of the antibody industry depends on the application of new technologies and platforms. This talk introduces Biointron’s many new technologies and platforms, ranging from antibody development, functional assays, to antibody optimization, such as VHH discovery platform, FCMES affinity maturation platform, AbDrop single B-cell sorting platform, etc. The talk also demonstrates Carterra’s remarkable contributions to these platforms, which have greatly improved the efficiency, quality and throughput. Numerous cases are displayed to share with the audience.
Speakers:
Dr. Long Xu earned his undergraduate degree from Nanjing University in China and completed his PhD at Boston University in the United States. With over a decade of experience, Dr. Xu worked at Washington University in St. Louis, Lighting Research Center, and other internationally renowned institutions. His research spans multiple disciplines within life sciences and health, including DNA damage and repair, DNA photoreactivation, lighting and health, etc. In 2022, he joined the Biointron team, focusing on the establishment of various high-quality antibody technology platforms, and dedicated to the discovery, optimization, and application research of antibodies.
Daniel Bedinger was instrumental in the launch of Carterra’s LSA platform, perfecting technology, applications and methods and now leads the company’s global Application Science team. He has over two decades of experience in the generation and characterization of therapeutic monoclonal antibodies—most notably at Xoma and Abgenix. Daniel earned his Ph.D. from UC Davis in Cellular and Molecular Physiology.
Register now: https://zoom.us/webinar/register/WN_hNjZT_-aQmiKEuo5l4DxTA#/registration